Year1
- 型号：
- 厄洛替尼片
- 规格：
- 150mg*30片/盒
- 有效期：
- 36个月
About % is absorbed after oral administration, and the bioavailability is significantly increased to almost % when taken with food. The half-life is about hours, and it is mainly eliminated through metabolism, and a small part is eliminated through metabolism. Absorption and Distribution) The bioavailability of Erlotinib at oral doses is approximately %, with peak plasma concentrations reaching 1 hour post-dose. Food can significantly increase bioavailability by almost %. Approximately % of erlotinib is bound to albumin and acid glycoproteins after absorption. )Erlotinib
The apparent volume of distribution is liters. Metabolism and clearance In vitro cytochrome enzyme analysis showed that erlotinib is mainly metabolized and, to a small extent, metabolized by extrahepatic isoenzymes. After an oral dose, % of the drug is recovered in the feces (% of the dose as unchanged form) and % (.% of the dose as unchanged form) in the urine. Pharmacokinetic analysis of patients taking a single dose of erlotinib showed that the median half-life was . Therefore it takes ~ days to reach steady-state plasma concentrations. There was no significant correlation between clearance rate and age. Smokers) the clearance rate of erlotinib
increased by %. Special population: patients with abnormal liver function) Erlotinib is mainly cleared in the liver. There is currently no data on the impact of abnormal liver function or liver metastasis on the pharmacokinetics of erlotinib. (See [Precautions] Patients with abnormal liver function, [Adverse Reactions] and [Usage and Dosage] Dosage adjustment). In patients with renal dysfunction, less than % is secreted in urine after a single dose. No clinical trials have been conducted in patients with abnormal renal function. Interactions) Erlotinib is primarily metabolized and thus its exposure may be increased by putative inhibitors. When combined with ketoconazole, a strong inhibitor of erlotinib, the efficacy of erlotinib is increased (see the dose adjustment section in [Drug Interactions] and [Dosage and Administration]). Use of the induction agent rifampicin before treatment or at the same time can increase the clearance of erlotinib and at the same time decrease the clearance of erlotinib (see [Drug Interactions] and [ Dosage and Dosage). In a phase 1 clinical trial, the pharmacokinetics of gemcitabine and erlotinib did not interact significantly.
Common name) Erlotinib hydrochloride tablets
Trade name) Tarceva
English namebr/> Chinese Pinyinbr/> [Main ingredients]
The main ingredients of this product are ) Erlotinib hydrochloride
.
)Tarceva
Each tablet contains)erlotinib
(in the form of)erlotinib hydrochloride
).
[Character] Indian tablets are round, biconvex, white coated tablets.
[Indications]
) Erlotinib
can be tried as a third-line treatment for locally advanced or metastatic non-small cell lung cancer that has failed two or more chemotherapy regimens. This indication is based on the results of the aforementioned phase III clinical study abroad. The efficacy of second-line treatment for Chinese non-small cell lung cancer needs to be confirmed by further clinical studies. Two multicenter, placebo-controlled, randomized phase III trials in the first-line treatment of patients with locally advanced or metastatic disease showed that there was no clinical benefit when taking erlotinib concurrently with platinum-based chemotherapy (carboplatin + paclitaxel or gemcitabine + cisplatin). benefit and is therefore not recommended as first-line treatment in these conditions.
[Usage and Dosage]
The recommended dose of erlotinib alone for non-small cell lung cancer is /day, taken at least one hour before or one hour after eating.
【Packaging】
Blister packaging sheet/box
【Storage】
Store at ℃. ~℃ is also acceptable. Medicines should be kept out of the reach of children.
[Specifications]
*Pieces/box
[Validity period]
Months
[Manufacturer]
Company name
India
WhatsApp
